Well-controlled asthma – principle of doctor and patient cooperation Review article

Main Article Content

Maciej Kupczyk

Abstract

The main goals of asthma therapy include achieving good disease control, and reduction of the risks due to exacerbations and impaired lung function. At the same time the risk of side effects associated with the treatment should be minimized. In case of lack of optimal control despite appropriate treatment, before considering an increase in the dose or change in the medication, the first step is to check the correctness of the inhalation techniques, to evaluate patients’ compliance, possible exposure to factors exacerbating the disease (tobacco smoke, allergens, drugs), co-morbidities that could deteriorate the course of asthma and correctness of the diagnosis. In the everyday clinical practice, the most common cause of lack of effectiveness of the treatment in patients with bronchial asthma is the lack of “compliance” or the wrong drug inhalation technique. In line with the GINA guidelines administration of the combo drugs (inhaled corticosteroid plus formoterol in one inhaler) as baseline treatment and reliever represents the optimal form of treatment.

Downloads

Download data is not yet available.

Article Details

How to Cite
Kupczyk , M. (2021). Well-controlled asthma – principle of doctor and patient cooperation. Alergoprofil, 17(4), 12-16. https://doi.org/10.24292/01.AP.174301021
Section
THERAPY

References

1. Global Strategy for Asthma Management and Prevention. Updated 2021. (access: 19.10.2021).
2. Kowalski ML, Jędrzejczak M, Cirlić M. Efektywność leczenia astmy oskrzelowej w Polsce w ocenie pacjentów – wyniki badania AIRCEE (Asthma Insights & Reality in Central and Eastern Europe). Alerg Astma Immunol. 2004; 9(4): 187-95.
3. Kuna P, Kupryś-Lipińska I, Dębowski T. Control of asthma in adults treated with beclomethasone and formoterol in extrafine particle aerosol formulation in a real-life setting in Poland – CASPER non-interventional, observational study. Pol Arch Med Wew. 2015; 125(10): 731-40.
4. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Resp Med. 2014; 24: 14009.
5. Reddel HK, Busse WW, Pedersen S et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017; 389(10065): 157-66.
6. O’Byrne PM, FitzGerald JM, Bateman ED et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018; 378(20): 1865-76.
7. Bateman ED, Reddel HK, O’Byrne PM et al. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018; 378(20): 1877-87.
8. Sobieraj DM, Weeda ER, Nguyen E et al. Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018; 319(14): 1485-96.
9. Papi A, Carradi M, Pigeon-Francisco C et al. Beclomethasone- formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomized controlled trial. Lancet Respir Med. 2013; 1: 23-31.
10. Vanelli M, Pedan A, Liu N et al. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther. 2009; 31(11): 2628-52.
11. Stanford RH, Shah MB, D’Souza AO et al. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012; 109: 403-7.
12. Kupczyk M, Kuna P. Astma Zero – zero tolerancji dla zaostrzeń astmy. Terapia. 2019; 27(4): 11-6.